BHP-01

N/A

Report date: 2025/05/18 20:00:07

Base Information

Drug NameBHP-01
Drug Alias NameBridge radiotherapy (Chengdu Brilliant Pharmaceutical)DLL3 Targeted α-PD-L1/4-1BB Modifying Chimeric Antigen Receptor T-cells (Chengdu Brilliant Pharmaceutical)BHP-01BHP01α-PD-L1/4-1BB DLL3 CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProgrammed death-ligand 1 modulatorsTumor necrosis factor receptor superfamily member 9 modulatorsDelta-like protein 3 modulators
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9Delta-like protein 3
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChengdu Brilliant Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSichuan UniversityChengdu Brilliant Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A